• Tue news: Pfizer explores sale of hospital drugs unit. FDA declines full approval of Ocaliva. AZ better than expected Q3 results. Pfizer, Lilly telehealth platforms draw scrutiny. 23andMe cutting lays off 40%. See more on our front page

Seeking sibling for Vyvgart, argenx files for FDA approval of subcutaneous efgartigimod

cafead

Administrator
Staff member
  • cafead   Sep 27, 2022 at 10:32: AM
via Argenx has filed for FDA approval of subcutaneous efgartigimod, keeping it on track to start selling the sibling of its existing intravenous generalized myasthenia gravis (gMG) treatment Vyvgart.

article source